BioMarin Pharmaceuticals
BMRN
BMRN
578 hedge funds and large institutions have $12.9B invested in BioMarin Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 101 funds opening new positions, 242 increasing their positions, 171 reducing their positions, and 55 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
578
Holders Change
+41
Holders Change %
+7.64%
% of All Funds
7.85%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.08%
New
101
Increased
242
Reduced
171
Closed
55
Calls
$97.7M
Puts
$87.7M
Net Calls
+$10M
Net Calls Change
-$2.19M
Top Buyers
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$114M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$85.4M |
| 3 |
Goldman Sachs
New York
|
+$76.6M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$59.1M |
| 5 |
Squarepoint
New York
|
+$49.2M |
Top Sellers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$272M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$96.1M |
| 3 |
Bank of New York Mellon
New York
|
-$72.2M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$56.5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$47.1M |
